Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 24 2021

Full Issue

Parsing Policy: GOP Disapproval Of HHS Nominee Is Laughable; Painful Truths About FDA's Opioid Mistake

As President Joe Biden attempts to fill his cabinet, editorial pages focus on important qualities needed from leaders in those positions.

Sen. Richard M. Burr (R-N.C.) is a thoughtful guy, and while he’s a reliable Republican vote on the vast majority of issues that come before the Senate, he’s independent enough to have voted to convict former President Trump at Trump’s second impeachment trial (but not the first one). So it was disturbing to hear Burr make the Republicans’ least principled argument Tuesday against California Atty. Gen. Xavier Becerra’s nomination to lead the U.S. Department of Health and Human Services: that only someone with significant work experience in the healthcare sector should serve in that post. (Jon Healey, 2/23)

During a year in which half a million Americans have died of Covid-19, it’s easy to overlook a much longer epidemic — the worst drug crisis in American history, a crisis fueled in part by the unholy alliance between F.D.A. officials and pharmaceutical companies. Since Eddie Bisch’s Florida fishing trip, at least 500,000 Americans have died of an opioid-related overdose. Millions now have what’s called opioid use disorder. Drug overdose deaths in the year ending May 2020 reached a record high. Meanwhile, the interim F.D.A. commissioner, Dr. Janet Woodcock, long known as the nation’s top drug cop, is reported to be under consideration by the Biden administration to permanently lead the agency. (Beth Macy, 2/23)

For several years now, some gun makers have been exploiting a loophole in federal regulations to evade a range of gun control measures by selling firearms in pieces to be assembled later by consumers, including people barred from owning a gun. It’s a preposterous situation, and the Biden administration should either address it through stronger regulations under existing congressional authority, or work with Congress on a legislative fix. The issue centers on so-called ghost guns, which consist of untraceable parts that can be ordered online and then, with a little finishing work, assembled into a working firearm. The gun parts fall outside federal regulation because the Bureau of Alcohol, Tobacco, Firearms and Explosives held that while the core section of a gun — called a receiver or a frame — meets the legal definition of a firearm, an incomplete receiver or frame does not. (2/24)

The United States possesses classified intelligence information about illnesses in the autumn of 2019, before the global pandemic, at the Wuhan Institute of Virology, or WIV, which was carrying out research on bat coronaviruses very similar in genetic makeup to the pandemic virus. The intelligence should be declassified, and soon. Then-Secretary of State Mike Pompeo and President Donald Trump missed no opportunity to bash China over the virus, trying to divert attention from Mr. Trump’s disastrous pandemic response. Setting aside this scapegoating, the origins of the coronavirus remain unknown. (2/22)

Drug developers see Food and Drug Administration approval as a difficult uphill climb, requiring large investments of resources and time. But when it comes to new drug applications and biologics license applications, it’s usually not the FDA that slows down the process. (William Feehery and Julie Bullock, 2/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 16
  • Monday, June 15
  • Friday, June 12
  • Thursday, June 11
  • Wednesday, June 10
  • Tuesday, June 9
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF